Loading company…
Wuhan Togo Biotechnology Co., Ltd, founded in 2013 in Wuhan, China, develops artificial livers for chronic or acute liver failure.
Founded in 2013 and based in Wuhan, China, Wuhan Togo Biotechnology Co., Ltd makes artificial livers, including HepAssis2, and mass-produces human-derived hepatoblast cells. It was established by professor Ping Zhou of the Institute of Organ Transplantation at Tongji Hospital, and had raised three funding rounds as of July 2022. The company plans to build an artificial hepatocyte factory in Chongqing and raise CNY 200 million in Series B1 funding by the end of 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in